Sees FY25 revenue $8.05B-$8.65B, consensus $8.5B. CEO Steve Cutler commented, “ICON (ICLR) continues to navigate dynamic clinical development market conditions, as trial activity has been ...
BofA analyst Michael Ryskin lowered the firm’s price target on Icon (ICLR) to $255 from $270 and keeps a Buy rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback